On Nov. 14 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Nov. 9 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Nov. 8 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration issued its weekly Enforcement Report for Nov. 8 that lists the status of recalls and field corrections for food, drugs, biologics and devices. The report covers both domestic and foreign firms.
The Food and Drug Administration is amending its regulations on food additives permitted in feed and drinking water of animals to allow the use of formic acid and ammonium formate as an acidifying agent and set limits on its use, FDA said. The final rule takes effect Nov. 13.
On Nov. 7 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Nov. 6 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On Nov. 3 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration is amending its color additive regulations to allow for the use of calcium carbonate to color hard and soft candy, mints and chewing gum, it said. The change was requested by Wm. Wrigley Jr. Company. The final rule takes effect Dec. 8.
The Food and Drug Administration on Nov. 6 issued a guidance document on recommended statements for over-the-counter drugs containing aspirin that are labeled with cardiovascular-related imagery. FDA regulations currently allow labeling for cardiovascular events only in professional labeling directed to healthcare professionals, the agency said. However, “FDA does not intend to take action against manufacturers of single-ingredient aspirin, buffered aspirin, and aspirin in combination with an antacid … because the product label includes cardiovascular related imagery such as the heart image, if the label also includes the following statement: Talk to your doctor or other healthcare provider before using this product for your heart,” the agency said.